University of Western Ontario, London, Ontario, Canada.
Arthritis Care Res (Hoboken). 2012 Sep;64(9):1405-14. doi: 10.1002/acr.21716.
This study was performed to determine the prevalence of elevated C-reactive protein (CRP) levels and the significance of CRP in clinical parameters in systemic sclerosis (SSc; scleroderma) patients.
Canadian Scleroderma Research Group data were used. Statistical comparisons were made for CRP levels ≤8 mg/liter versus >8 mg/liter, early (≤3 years from first non-Raynaud's phenomenon symptom) versus late SSc, and diffuse cutaneous SSc (dcSSc) versus limited cutaneous SSc (lcSSc). A survival analysis was analyzed between patients with normal versus elevated CRP levels.
A total of 1,043 patients (mean ± SD age 55.4 ± 12.1 years, mean ± SD disease duration of 11.0 ± 9.5 years) were analyzed; elevation of CRP level and erythrocyte sedimentation rate (ESR; >20 mm/hour) occurred in 25.7% and 38.2%, respectively. Mean ± SD baseline CRP level in dcSSc (11.98 ± 25.41 mg/liter) was higher than in lcSSc (8.15 ± 16.09 mg/liter; P = 0.016). SSc patients with an early disease duration had a higher mean ± SD CRP level (12.89 ± 28.13 mg/liter) than those with a late disease duration (8.60 ± 17.06 mg/liter; P = 0.041). Although not consistent in all subsets, CRP was significantly associated (P < 0.01) with ESR, modified Rodnan skin score (MRSS), worse pulmonary function parameters, disease activity, damage, and Health Assessment Questionnaire. CRP level seemed to normalize in many SSc patients over time. Total lung capacity <80% predicted, MRSS, and serum creatinine were predictors of elevated CRP levels in SSc (odds ratio [OR] 2.76 [95% confidence interval (95% CI) 1.73-4.40], P = 0.0001; OR 1.03 [95% CI 1.01-1.05], P = 0.005; and OR 1.005 [95% CI 1.001-1.010], P = 0.02, respectively). Survival for patients with elevated CRP levels was less than for patients with normal CRP levels (P = 0.001).
CRP level is elevated in one-quarter of SSc patients, especially early disease. It is correlated with disease activity, severity, poor pulmonary function, and shorter survival.
本研究旨在确定 C 反应蛋白(CRP)水平升高的患病率以及 CRP 在系统性硬化症(SSc;硬皮病)患者临床参数中的意义。
使用加拿大硬皮病研究组的数据。对 CRP 水平≤8mg/L 与>8mg/L、早期(从首发雷诺现象症状起≤3 年)与晚期 SSc、弥漫性皮肤型 SSc(dcSSc)与局限性皮肤型 SSc(lcSSc)进行统计学比较。对 CRP 水平正常与升高的患者进行生存分析。
共分析了 1043 例患者(平均年龄±标准差为 55.4±12.1 岁,平均病程±标准差为 11.0±9.5 年);CRP 水平升高和红细胞沉降率(ESR;>20mm/小时)分别发生在 25.7%和 38.2%的患者中。dcSSc 患者的平均基线 CRP 水平(11.98±25.41mg/L)高于 lcSSc 患者(8.15±16.09mg/L;P=0.016)。疾病早期患者的平均 CRP 水平(12.89±28.13mg/L)高于疾病晚期患者(8.60±17.06mg/L;P=0.041)。虽然在所有亚组中并不一致,但 CRP 与 ESR、改良 Rodnan 皮肤评分(MRSS)、更差的肺功能参数、疾病活动度、损伤以及健康评估问卷显著相关(P<0.01)。CRP 水平似乎随着时间的推移在许多 SSc 患者中趋于正常。肺活量<80%预测值、MRSS 和血清肌酐是 SSc 患者 CRP 水平升高的预测因素(优势比[OR]2.76[95%置信区间(95%CI)1.73-4.40],P=0.0001;OR 1.03[95%CI 1.01-1.05],P=0.005;OR 1.005[95%CI 1.001-1.010],P=0.02)。CRP 水平升高的患者的生存时间短于 CRP 水平正常的患者(P=0.001)。
四分之一的 SSc 患者 CRP 水平升高,尤其是疾病早期。它与疾病活动度、严重程度、肺功能差和生存率降低相关。